SÍNDROMES MIELODISPLÁSICAS
LUSPATERCEPT UTILIZATION PATTERNS IN LOWER-RISK MYELODYSPLASTIC SYNDROMES: FINDINGS FROM A MULTINATIONAL MEDICAL RECORD REVIEW STUDY
M Díez-Campeloa, A Yucelb, RK Goyalc, MB Glassbergd, EM Cavalcantee, E Esterbergc, J Rombif, KL Davisc, D Mitevae, U Germingg,h
a Hematology Department, Institute of Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, Salamanca, Spain
b Bristol Myers Squibb (BMS), Princeton, United States
c RTI Health Solutions, Research Triangle Park, United States
d Bristol Myers Squibb (BMS), Madison, United States
e Bristol Myers Squibb (BMS), São Paulo, SP, Brazil
f RTI Health Solutions, Lyon, France
g Celgene International Sàrl, a Bristol-Myers Squibb (BMS) Company, Boudry, Switzerland
h University Hospital of Dusseldorf (UKD), Dusseldorf, Germany
Lido
376
Vezesque se leu este artigo
123
Total PDF
253
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 29 | 12 | 41 |
| 2025 5 | 42 | 12 | 54 |
| 2025 4 | 29 | 8 | 37 |
| 2025 3 | 36 | 7 | 43 |
| 2025 2 | 35 | 12 | 47 |
| 2025 1 | 19 | 11 | 30 |
| 2024 12 | 16 | 7 | 23 |
| 2024 11 | 31 | 32 | 63 |
| 2024 10 | 16 | 22 | 38 |
